Comparing the effect of Sitagliptin versus Glimepiride on lipid profile and BMI in known case of Type 2 Diabetes Mellitus

Abstract

Background: Diabetes mellitus, the most common endocrine disease is represented by metabolic abnormalities due to relative or absolute deficiency of insulin and or insulin resistance. Dyslipidemia which is characterized by increased plasma levels of triglycerides
(TG), low-density lipoprotein cholesterol (LDL-C) and decreased level of high-density lipoprotein cholesterol (HDL-C) is commonly seen in patients with type 2 diabetes. Metformin and Sulfonylureas (SU) like Glimepiride are the most commonly used oral antidiabetic agents. However, SU causes hypoglycemia and weight gain and hence, patients are shifted to other antidiabetic agents like Sitagliptin (DPP-4) inhibitor or insulin therapy Objective: To study was to assess the effect of Sitagliptin a (DPP-4 inhibitor) oral antidiabetic drug with Glimepiride on, BMI and dyslipidemia in type 2 diabetic patients. Material and Methods: This prospective comparative observational study was conducted in general medicine outpatient department at BRIMS teaching hospital, Bidar. The study starts from June 2022 to June 2023. The study period was 24 weeks. Group A: 75 Cases will be on Tab Sitagliptin 50 mg OD for 24 weeks. Patients will be asked to come for follow up at 12th week and 24th week. Group B: 75 Cases will be on Tab Glimepiride 1mg BD for 24 weeks. Results: There was reduction in BMI in Sitagliptin group (25.03 ±4.64 to 23.93 ±3.91) while Glimepiride showed a slight increase in body mass index (25.9± 4.47 to 26.3± 3.96). At 24 weeks, in comparison to Glimepiride group, Sitagliptin group had considerable reduction of Total Cholesterol, Triglycerides, and LDL-C while there was increase in HDL-C levels Speaking of Glimepiride. There was significant difference between both the groups with p value < 0.05 for all the parameters. Conclusion: Sitagliptin though primarily used in diabetes mellitus for the control of blood sugar, its favorable effects on BMI, and serum lipid cannot be denied. Hence Sitagliptin seems to be better option than Glimepiride